Best for
Mobile
How to buy Acorda Therapeutics shares
Own Acorda Therapeutics shares in just a few minutes. Share price changes are updated daily.
Acorda Therapeutics, Inc (ACOR) is a leading biotechnology business based in the US. Acorda Therapeutics is listed on the NASDAQ and employs 344 staff. All prices are listed in US Dollars.
How to buy shares in Acorda Therapeutics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ACOR in this case.
- Research Acorda Therapeutics shares. The platform should provide the latest information available.
- Buy your Acorda Therapeutics shares. It's that simple.
What's in this guide?
- Can I buy shares in Acorda Therapeutics?
- Acorda Therapeutics shares summary
- Compare share dealing platforms
- Is Acorda Therapeutics stock a buy or sell?
- Can I short Acorda Therapeutics shares?
- Are Acorda Therapeutics shares over-valued?
- Acorda Therapeutics's financials
- How volatile are Acorda Therapeutics shares?
- Does Acorda Therapeutics pay a dividend?
- Have Acorda Therapeutics shares ever split?
- Other common questions
Acorda Therapeutics share price
Use our graph to track the performance of ACOR stocks over time.Acorda Therapeutics shares at a glance
Information last updated 2021-01-23.
| 52-week range | $2.5344 - $14.22 |
|---|---|
| 50-day moving average | $4.9333 |
| 200-day moving average | $4.324 |
| Wall St. target price | $23 |
| PE ratio | 1.2394 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $6.132 |
Invest in Acorda Therapeutics shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Acorda Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Acorda Therapeutics under- or over-valued?
Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acorda Therapeutics's P/E ratio
Acorda Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Acorda Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Acorda Therapeutics's PEG ratio
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Acorda Therapeutics financials
| Revenue TTM | $165.3 million |
|---|---|
| Gross profit TTM | $157.6 million |
| Return on assets TTM | -6.37% |
| Return on equity TTM | 16.51% |
| Profit margin | 29.71% |
| Book value | $39.434 |
| Market capitalisation | $72.1 million |
TTM: trailing 12 months
How to short and sell Acorda Therapeutics shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "ACOR.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 2.5 million Acorda Therapeutics shares held short by investors – that's known as Acorda Therapeutics's "short interest". This figure is 4.3% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.
Acorda Therapeutics's "short interest ratio" (SIR)
Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 3.6 million). Acorda Therapeutics's SIR currently stands at 0.69. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 690 shares are currently held short.
However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0489% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.
Find out more about how you can short Acorda Therapeutics stock.
Acorda Therapeutics share dividends
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have Acorda Therapeutics's shares ever split?
Acorda Therapeutics's shares were split on a 1:6 basis on 4 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.
Acorda Therapeutics share price volatility
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $2.5344 up to $14.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.7511. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Acorda Therapeutics overview
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Frequently asked questions
More guides on Finder
-
How to buy Acorda Therapeutics shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Acorda Therapeutics shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert